IDT receives FDA Warning Letter
Filed with ASX · · 1 page · English
Earlier from IDT Australia
- Divestment of Selected Generic Product Portfolio
- Replacement Appendix 4D
- Strategic and Operational Review Update
- Appointment interim Chief Executive Officer
- IDT Executes API Development Agreement
Later from IDT Australia
- Update - Response to FDA Warning Letter
- Appointment of Chief Executive Officer
- and Cann Group Medicinal Cannabis Partnership
- Preliminary Final Report
- On-Market Share Buy-back and Small Parcel Buy-back
Follow IDT Australia into a list and get an email when it puts out news.
Follow IDT Australia